Advertisement
IQV vs TMO
Which Stock Would AI Choose? IQVIA Holdings (IQV) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- IQV is a leading provider of clinical research, data analytics, and healthcare services, with upcoming second-quarter results expected to highlight revenue growth amid analyst optimism.
- TMO delivered a strong second-quarter earnings beat on July 23, 2026, with revenue of $11.99 billion and raised full-year guidance, driving recent share price gains.
- Over recent market activity, TMO shares have shown stronger upward momentum compared with IQV, which trades near recent levels ahead of its July 28 earnings report.
- Both companies operate in the healthcare and life sciences sector, with IQV focused on outsourced research and data solutions while TMO emphasizes instruments, reagents, and diagnostics.
- Market sentiment has favored TMO following its earnings release, while IQV benefits from analyst price target increases and share repurchase activity.
- Relative performance reflects differences in business exposure, with TMO exhibiting greater recent stability in earnings delivery.
Introduction
This comparison examines IQV and TMO, two established players in the healthcare and life sciences industries. The analysis focuses on business models, recent performance trends, and market positioning to assist investors and traders evaluating relative opportunities in the sector. Professionals seeking exposure to clinical research outsourcing or scientific instrumentation and diagnostics may find the review relevant when assessing diversification or tactical allocations within healthcare equities.
IQV Overview and Recent Performance
IQV, or IQVIA Holdings Inc., delivers clinical research services, healthcare data analytics, and commercial solutions primarily to pharmaceutical and biotechnology companies. In recent weeks, the stock has traded in a range influenced by broader market conditions and anticipation of its second-quarter earnings report scheduled for July 28, 2026. Analysts project revenue near $4.3 billion and earnings per share of $3.02. Year-to-date returns stand at approximately 7.7%, with one-year performance around 3.6%. Recent analyst activity includes several upward revisions to price targets, reflecting confidence in long-term growth drivers such as real-world evidence platforms and operational efficiency initiatives. Sentiment remains constructive ahead of results, supported by prior share repurchase authorizations.
TMO Overview and Recent Performance
TMO, or Thermo Fisher Scientific Inc., provides life science solutions including instruments, reagents, consumables, and diagnostics services. The company reported robust second-quarter 2026 results on July 23, with revenue reaching $11.99 billion and adjusted earnings per share exceeding consensus estimates. Management raised full-year earnings per share guidance to a range of $24.93 to $25.33. Over the past 30 days, shares advanced approximately 14.6%, reflecting positive investor response to the earnings beat and improved demand outlook across end markets. Year-to-date returns are approximately 1.74%, while one-year performance reaches about 20%. Recent market activity highlights sustained institutional interest and upward price target adjustments following the report.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the platform’s highest-performing AI trading bots selected from hundreds of available systems that cover thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions, consistent trend capture, and favorable risk-adjusted statistics earn placement in this section. Available bots exhibit a wide range of trading styles, timeframes, and performance profiles, with select agents reporting historical returns exceeding 100% in backtested scenarios and win rates in the 70–80% range across various instruments. These systems differ in strategy focus, including short-term signal generation and longer-horizon positioning. Traders interested in automated approaches may explore the curated selection for further details.
Head-to-Head Comparison
IQV and TMO operate in overlapping healthcare spaces yet pursue distinct business models. IQV centers on outsourced clinical development, data analytics, and real-world evidence generation, exposing it to pharmaceutical research and development spending cycles. TMO supplies essential tools, reagents, and diagnostic platforms, benefiting from recurring demand in research laboratories and clinical settings. Recent momentum favors TMO following its earnings delivery and guidance raise, while IQV awaits its report amid generally positive analyst sentiment. Risk factors include regulatory and funding environments for both, though TMO’s broader product diversification may offer relative stability. Sector exposure remains healthcare-centric, with market sentiment currently tilted toward companies demonstrating clear earnings visibility.
Tickeron AI Verdict
Based on observable factors such as recent earnings consistency, upward guidance revisions, and positive price momentum in the latest reporting period, Tickeron’s AI systems would likely assign a higher probabilistic preference to TMO over IQV in the current environment. Trend stability and catalyst delivery appear more pronounced for TMO, though outcomes remain subject to broader market conditions and subsequent earnings results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IQV is a Hold and TMO is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IQV’s FA Score shows that 1 FA rating(s) are green whileTMO’s FA Score has 3 green FA rating(s).
- IQV’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IQV’s TA Score shows that 5 TA indicator(s) are bullish while TMO’s TA Score has 3 bullish TA indicator(s).
- IQV’s TA Score: 5 bullish, 4 bearish.
- TMO’s TA Score: 3 bullish, 4 bearish.
Price Growth
IQV (@Medical Specialties) experienced а +3.91% price change this week, while TMO (@Medical Specialties) price change was +2.74% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.00%. For the same industry, the average monthly price growth was +7.63%, and the average quarterly price growth was +23.29%.
Reported Earning Dates
IQV is expected to report earnings on Nov 04, 2026.
TMO is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Medical Specialties (-1.00% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| IQV | TMO | IQV / TMO | |
| Capitalization | 39.8B | 220B | 18% |
| EBITDA | 3.53B | 12B | 29% |
| Gain YTD | 7.147 | 3.042 | 235% |
| P/E Ratio | 30.04 | 32.07 | 94% |
| Revenue | 17B | 46.3B | 37% |
| Total Cash | 2.08B | 4.06B | 51% |
| Total Debt | 16.2B | 42.5B | 38% |
IQV | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 76 | 31 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 67 Overvalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 81 | |
SMR RATING 1..100 | 42 | 61 | |
PRICE GROWTH RATING 1..100 | 7 | 10 | |
P/E GROWTH RATING 1..100 | 38 | 33 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (12) in the Medical Specialties industry is somewhat better than the same rating for IQV (67) in the Servicestothe Health Industry industry. This means that TMO’s stock grew somewhat faster than IQV’s over the last 12 months.
TMO's Profit vs Risk Rating (81) in the Medical Specialties industry is in the same range as IQV (100) in the Servicestothe Health Industry industry. This means that TMO’s stock grew similarly to IQV’s over the last 12 months.
IQV's SMR Rating (42) in the Servicestothe Health Industry industry is in the same range as TMO (61) in the Medical Specialties industry. This means that IQV’s stock grew similarly to TMO’s over the last 12 months.
IQV's Price Growth Rating (7) in the Servicestothe Health Industry industry is in the same range as TMO (10) in the Medical Specialties industry. This means that IQV’s stock grew similarly to TMO’s over the last 12 months.
TMO's P/E Growth Rating (33) in the Medical Specialties industry is in the same range as IQV (38) in the Servicestothe Health Industry industry. This means that TMO’s stock grew similarly to IQV’s over the last 12 months.
| IQV | TMO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 59% | 2 days ago 62% |
| Stochastic ODDS (%) | 2 days ago 73% | 2 days ago 64% |
| Momentum ODDS (%) | 2 days ago 64% | N/A |
| MACD ODDS (%) | 2 days ago 67% | 2 days ago 57% |
| TrendWeek ODDS (%) | 2 days ago 62% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 66% | 2 days ago 61% |
| Advances ODDS (%) | 4 days ago 60% | 4 days ago 62% |
| Declines ODDS (%) | 2 days ago 66% | 2 days ago 63% |
| BollingerBands ODDS (%) | 2 days ago 56% | 2 days ago 68% |
| Aroon ODDS (%) | 2 days ago 50% | 2 days ago 54% |
Advertisement
IQV and
Correlation & Price change
A.I.dvisor indicates that over the last year, IQV has been closely correlated with CRL. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if IQV jumps, then CRL could also see price increases.
| Ticker / NAME | Correlation To IQV | 1D Price Change % | ||
|---|---|---|---|---|
| IQV | 100% | -0.08% | ||
| CRL - IQV | 72% Closely correlated | -1.09% | ||
| TMO - IQV | 69% Closely correlated | -1.18% | ||
| MEDP - IQV | 65% Loosely correlated | -2.52% | ||
| RVTY - IQV | 62% Loosely correlated | -0.32% | ||
| A - IQV | 60% Loosely correlated | +0.71% | ||
More | ||||
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.